Zeneca Limited

E.i. Dupont De Nemours and Company

Imperial Chemical Industries Limited

Rohm and Haas Electronic Materials Korea Ltd.

Dupont Electronics, Inc.

Charles D McLaren

Marc Jerome Chapdelaine

Ying Wang

Jerald Feldman

Kerwin D Dobbs

Jeffrey Alan McKinney

Timothy W Davenport

Laura Enid Garcia-Davenport

Nora Sabina Radu

Adam Fennimore

Paul Francis Jackson

Norman Herron

Weiying Gao

Vsevolod Rostovtsev

Michael Henry Howard, Jr

Weishi Wu

Daniel David Lecloux

Paul F Jackson

Thomas Michael Bare

Gene M Rossi

Chi-Sik Kim

Viacheslav V Diev

Frederick P Gentry

James Roy Empfield

Richard Bruce Sparks

Soo-Yong Lee

Troy C Gehret

Giang Dong Vo

Seung-Hoon Yoo

Yoo-Jin Doh

Mi-Ran Seo

Yunlong Zou

The present disclosure relates to a plurality of light-emitting materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound or a specific combination of compounds according to the present disclosure as a host material and/or a dopant material, it is possible to provide an organic electroluminescent device having improved driving voltage, luminous efficiency and/or lifetime properties compared to conventional organic electroluminescent devices.

Plurality of light-emitting materials, organic electroluminescent compound, and organic electroluminescent device comprising the same

This invention relates to triarylamine compounds and compositions including such compounds, that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a compound or composition. The triarylamine compound can be present as a hole transport material in a hole transport layer. The triarylamine compound can also be present in a photoactive layer in combination with an organometallic compound capable of electroluminescence having an emission maximum between 380 and 750 nm.

High energy triarylamine compounds for hole transport materials

This invention relates to a composition including (a) a dopant, (b) a first host having at least one unit of Formula I, and (c) a second host compound. Formula I has the structure where Q is a fused ring linkage having the formula In Formula I: Ris the same or different at each occurrence and is D, alkyl, aryl, silyl, alkoxy, aryloxy, cyano, vinyl, or allyl; Ris the same or different at each occurrence and is H, D, alkyl, or aryl, or both Rare an N-heterocycle; Ris the same or different at each occurrence and is H, D, cyano, alkyl or aryl; and a is the same or different at each occurrence and is an integer from 0-4.

Compositions for electronic applications

There is provided a compound having Formula II In Formula II: R-Rare the same or different at each occurrence and can be D, alkyl, silyl, aryl, deuterated alkyl, deuterated silyl, or deuterated aryl; a and c are the same or different and are an integer from 0-5; and b and d are the same or different and are an integer from 0-4.

Blue luminescent compounds

The invention relates to pyridazinoquinoline compounds of the formulas B and B&prime;

Pyridazino quinoline compounds

Antagonists at the NMDA receptor complex which are benz�b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Substituted nitrogen heterocycles

Antagonists at the NMDA receptor complex which are benz[b]azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

A method for the treatment of neurological disorders, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I or of formula II (formulae set out on pages following the Examples), wherein

Therapeutic benzazapine compounds

Antagonists at the NMDA receptor complex which are benz b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Therapeutic benzazarine compounds

Growing community of inventors

Landenberg, PA, United States of America

Charles D McLaren